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EXTENSIVE quantitative experiments by Skipper, Schabel and Wilcox (1964,
1965) on the effects of certain antitumour agents on L 1210 leukaemic cells have
shown that prolongation of host survival by these drugs is not due to a slowing of
the growth rate of leukaemic cells, nor to induction of a lag in cell division, but to
the apparent disappearance of part of the leukaemic cell population. Cells that
remain continue to proliferate at the normal rate.
"Disappearance " of part of a proliferating population as measured in such
experiments is not necessarily synonymous with death of cells, for these effects
could have been produced just as well if the affected part of the population had
been sterilized, i.e., rendered incapable of cell division. There is, in fact, good
evidence that many commonly used antitumour agents act in the main by
impairing cell reproductive integrity. This lesion may be manifested in several
ways. Cells may be unable to divide but continue to grow, forming giant cells
which eventually die, or mitosis may be attempted but fail because of chromo-
somal damage. In mild impairment, ability to divide repeatedly is limited,
although one or a few successive divisions may be completed. Even though
impaired reproductive integrity does not necessarily cause the rapid death of
the affected cells, it decreases or eliminates their contribution to succeeding
populations.
Experimental evidence for impairment of cell reproductive integrity may
consist of a reduction in colony-formation in vivo (Till and McCulloch, 1961;
Bush and Bruce, 1964; Bruce, Meeker and Valeriote, 1966; Bruce and Meeker,
1967) or in vitro (Levis, 1963; Berry, 1964), giant-cell formation (Puck and
Marcus, 1956; Levis and de Nadai, 1964; Layde and Baserga, 1964; Kundel and
Nies, 1965), mitotic abnormalities (Ryan, Boddington and Spriggs, 1965; Nasjleti
and Spencer, 1966) or a reduction in population growth rate (Tomizawa and
Aronow, 1960; Dewey, Humphrey and Cork, 1963).
Many antitumour agents are also immunosuppressive, and there is evidence,
discussed elsewhere (Berenbaum, 1969) that their main mode ofaction on immuno-
logically competent cells is to impair reproductive integrity.
Dose-response relations for impairment of cell reproductive integrity by anti-
tumour and immunosuppressive agents are therefore of considerable practical
importance as they are the foundation ofrationally designedtherapeutic regimens.
* Present address: Department of Experimental Pathology, St. Mary's Hospital Medical School,
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In many cases, the dose-response relation is exponential, that is, the fraction F
ofa population surviving a dose D ofagent is givenby
F e-D (1e)
In this case a plot of log F against D is a straight line with a slope of -x inter-
cepting the zero ordinate (D 0) where F = 1. This relationship is most
readily accounted for by supposing the existence in the cell of a single vital target
inactivated by random contact with discrete quanta of the agent. The existence
of a repair mechanism or the necessity to inactivate multiple targets in each cell
gives the curve a shoulder near its origin. An approximation to this latter type
of curve is given by
F e1-(1 e-D)f. (2)
Exponential curves are typical of radiation, administered in vivo or in vitro
(Puck and Marcus, 1956; Robinson et al., 1967; Elkind and Whitmore, 1967) but
are also given by cells exposed in vitro to various alkylating agents (Levis, 1963;
Berry, 1964) or 5-fluorouracil (Madoc-Jones and Bruce, 1967).
Many attempts have been made to fit to an exponential relation dose-response
curves obtained in vivo for agents other than radiation. The fit is undoubtedly
good with cyclophosphamide and 1,3-bis (2-chloroethyl)-1-nitrosourea (Skipper,
Schabel arid Wilcox, 1964, 1965). However, the curves obtained for the destruc-
tion of murine leukaemic cells by such agents as 6-mercaptopurine and metho-
trexate cannot be regarded as exponential (Fig. 1A). In Fig. LB these data of
Skipper et al. (1965) are re-plotted with the dose on a logarithmic instead of a
linear scale and it can be seen that the points can now be fitted to straight lines.
If the slope of such a line is -y and its intercept on the F =1 axis is Do, then
Log F -y (log D - log Do)
and therefore
F D or FDY _ D Y. (3)
In other words, dose-response curves of L 1210 cells in mice treated with
methotrexate, 5-fluorouracil or 6-mercaptopurine are not exponential but hyper-
bolic in form, the product ofthe surviving fraction and the dose (or a power ofthe
dose) being a constant. Wheny = 1, cell survival is simply inversely proportional
to dose, and the product of the surviving fraction and the dose is equal to the
threshold dose Do.
The fact that results of experiments with cell-sterilizing agents are not often
plotted in this way in the literature, and the persisting myth that antitumour
agents are generally radiomimetic perhaps account for this quite common relation-
ship having been overlooked. A good example of a hyperbolic dose-response
curve with a slope of -1 was given by Berry (1964) for the action of manno-
mustine on cells in vitro. Berry pointed out that this curve was evidence that
mannomustine was not " radiomimetic " as radiation gave an exponential curve.
It has to be emphasized that, if the experimental results are determined over too
restricted a dose-range, it may not be possible to say whether a dose-response
curve is exponential or hyperbolic. This is the case, for instance, with the data
for 5-fluorouracil given by Skipper et al. (1965) covering a 5-fold dose range
(Fig. 1) and those of Bruce, Meeker and Valeriote (1966) and Bruce and Meeker
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FIG. 1.-Data of Skipper et al. (1965) on survival of L 1210 leukaemic cells after various doses
of antimetabolites in vivo. Leukaemic cells given intraperitoneally (-0 0-) or
intravenously (-OO-); drugs given intraperitoneally 1 day later. Fractional
survival of leukaemic cells estimated from prolongation of life span of treated animals.
A-log. survival plotted against dose on linear scale.
B-log. survival plotted against log. dose.
(1967) for the same drug, covering 4- to 10-fold dose-ranges. In both cases the
points would fit exponential and hyperbolic curves equally well.
As many antineoplastic agents are also immunosuppressive, dose-response
relations for this effect were accordingly investigated.
MATERIALS AND METHODS
Animal8
Colony-bred male A2G mice, weighing 16-24 g. at the start of the experiment,
were obtained from Animal Suppliers Ltd.
Immunization
Formalized sheep red cells (Burroughs Wellcome Ltd.) were washed twice in
saline and 0.2 ml. of a 10 % suspension injected intraperitoneally.
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Drugs
Cyclophosphamide (Ward Blenkinsop Ltd.) and sodium methotrexate (Lederle
Laboratories Ltd.) were dissolved in saline. Melphalan (Burroughs Weilcome
Ltd.) was dissolved in acid alcohol and buffer according to the manufacturer's
instructions. Aniline mustard (C.B.1074) obtained from the Chester Beatty
Research Institute, was dissolved in dimethyl sulphoxide. These drugs were
given intraperitoneally. 5-Fluorouracil (Roche Products Ltd.) and 6-thioguanine
(Koch-Light Laboratories Ltd.) were suspended in 0*5 % methylcellulose (Dow
Chemical Co.) in saline and injected subcutaneously. All solutions or suspensions
were prepared immediately before injection, the injection volume being 1 ml./
100 g. body weight. Drugs were given to groups ofeight mice for each dose-level
2 days after injecting sheep red cells. Control mice were given the solvent or
suspending agent only.
Plating technique
Spleens were removed 5 days after immunization and the numbers of haemo-
lysin-producing cellsthey contained countedbyJerne's method (Jerne andNordin,
1963; Jerne, Nordin and Henry, 1963). Full technical details are given elsewhere
(Berenbaum, 1967). Although the peak number of plaque-forming cells is found
4 days after immunization, sampling was carried out on the 5th day because it is
at this time that the maximum differences between control and treated animals
appear (Berenbaum, 1966).
RESULTS
Results ofrepresentative experiments are shown in Fig. 2, in which the number
ofplaques per spleen (expressed as a fraction ofthe control number) is plotted on
a logarithmic scale against dose. The scale for dose is linear in the case of the
alkylating agents aniline mustard, cyclophosphamide and melphalan, and loga-
rithmic in the case oftheantimetabolitesmethotrexate, 6-thioguanine and5-fluoro-
uracil. It is evident that these scales allow straight lines to be drawn through
the experimental points over most ofthe dose range, although there is a tendency
for the dose-response curves for methotrexate and 6-thioguanine to flatten out in
the lethal dose range. The dose-response curves for the alkylating agents used
here are therefore exponential, whereas those for the antimetabolites have a
hyperbolic form.
DISCUSSION
The results presented here, and those of Skipper, Schabel and Wilcox (1964,
1965) suggest that there is a fundamental difference between the dose-response
curves given by radiation and alkylating agents, which are exponential, and those
given by antimetabolites, which are hyperbolic. The reason for this difference
can only be a matter for speculation at present, but one explanation is that the
interaction between a molecule ofalkylating agent or an ionizing event on the one
hand and a cell component on the other does not affect the probability of other,
similar interactions, either simultaneous or subsequent, whereas the interaction
between a molecule of antimetabolite or metabolite and an enzyme site strongly
affects the probability of another such reaction. The dose-response relation for
alkylating agents and ionizing radiation is therefore governed by classic target
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FIG. 2.-Reduction in plaque-forming cells by various doses of antimetabolites and alkylating
agents. Sheep red cells given intraperitoneally on day 0 and drugs on day +2; plaque-
forming cells counted on day +5. The log. mean and log. standard deviations of the
numbers of plaque-forming cells in groups of eight mice are plotted against log. dose for
antimetabolites and against dose on a linear scale for alkylating agents. Duplicate experi-
ments are represented by different symbols (@, 0).
theory and it is easy to show that the relation to be expected is an exponential
one (Crowther, 1924; Lea, 1955; Elkind and Whitmore, 1967). Antimetabolites,
in contrast, act essentially by competition with natural metabolites for enzyme
sites. The relation to be expected here is indicated by the rate equation for
competitive inhibition of an enzyme (Webb, 1963),
vm (S) + K + I(S) (4)
Vm -(S) +K8[1+ (I)IKi]
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where Vi is the rate of the inhibited reaction, Vm the maximal rate at enzyme-
saturating substrate concentration, (S) and (I) the concentrations ofsubstrate and
inhibitor, and K. and Ki the dissociation constants for the enzyme-substrate and
enzyme-inhibitor complexes. The variation of reaction rate with inhibitor
concentration is shown in Fig. 3, curve A, both parameters being plotted on
logarithmic scales. It can be seen that, the higher the concentration ofinhibitor,
the more closely the relation between reaction rate and inhibitor concentration
approximates to a hyperbolic one. At low concentrations, the rate approaches
that of the uninhibited reaction asymptotically.
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FIG. 3.-Relation between cell survival and competitive inhibition of an enzyme concerned
in cell reproduction. Curve A shows the relation between concentration ofinhibitor [I] and
relative enzyme activity (Vi/Vm, left-hand ordinate). In this example, substrate concentra-
tion = 100, Ki = K8 = 1 (equation 4). The left-hand ordinate also indicates cell
survival expected if survival probability is proportional to the rate of the reaction mediated
by the enzyme. The right-hand ordinate shows cell survival expected, F, if cells normally
contain twice as much of this enzyme as is needed for normal proliferation. In this case,
the F = 1 abscissa is shifted downwards (B) and is cut by curve A at a threshold dose.
Curve C shows cell survival expected ifthere is dose-dependent repair (equation 5). In this
example [S], Ki and K are as in curve A, a = 106, b = 3.
Now, the fraction of a cell population that survives and reproduces is equal to
the average probability that its component cells retain reproductive integrity. It
may reasonably be suggested that this probability for any individual cell is
directly related to the rates at which critical enzyme-mediated reactions can be
carried out during the proliferative cycle. It would then follow, as shown in
Fig. 3, that, at high concentrations of antimetabolite, the surviving fraction of a
cell population would be inversely related to the concentration. Other factors
being equal, the in vivo concentration ofa drug is proportional to the dose. There-
fore, at high doses the surviving fraction of a cell population will be inversely
proportional to the dose of antimetabolite while, at low doses, cell survival will
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approach the F = 1 abscissa asymptotically. The experimentally determined
survival curves, however, cut the F 1 abscissa at a threshold dose. Two
possible explanations for this may be considered. Firstly, some enzymes con-
cerned in cell proliferation may be present in excess, so that proliferation is not
impaired until a certain proportion ofenzyme has been blocked. In other words,
the surviving fraction of a proliferating population may not fall below 1 until the
rate of the reaction mediated by the enzyme falls to 0.5, or some other fraction,
of that in untreated cells. In effect, this would result in a shift in the abscissae
for cell survival (Fig. 3B) andthe curve would cuttheF = 1 abscissa at athreshold
dose.
Secondly, the existence of a threshold dose could be explained by dose-depen-
dent repair mechansims. If fractional cell survival F in the absence of repair is
proportional to residual enzyme activity (Vi/Vm in equation 4), allowance for
repair that decreases in effectiveness with increasing dose may be made by
appropriate modification ofequation (4), for instance, by adding to the right hand
side ofthe equation a factor inversely proportional to the dose, or a power of the
dose.
F = (AS + (A)
(S) + K8LL + (I)/Ki] ± (I)b (5)
where b > 0. Equation 5 generates a family of curves such as Fig. 3, curve C.
These closely approach curve A at high doses, but increasingly diverge from it at
lower doses to cut the F 1 abscissa.
It is not clear why some antimetabolites give hyperbolic dose-response curves
with slopes steeper than -1 (Fig. 1, 6-mercaptopurine; Fig. 2, 5-fluorouracil).
It is possible that such curves are produced when lesions caused by the agent
interact. Alternatively they may be accounted for by repair mechanisms that
are more effective at low doses (with b > 1 in equation 5). In this case the dose-
response curve would have an initially steeper portion, and approach a slope of
-1 at doses at which repair became relatively ineffective.
It is also interesting to note that the character ofthe dose-response curve given
by one and the same agent may depend on whether it is determined in vitro or
in vivo. For instance, 5-fluorouracil, which gives hyperbolic curves in vivo (Fig. 2)
gives exponential curves when tested on L-cells in vitro (Madoc-Jones and Bruce,
1967). Again, mannomustine gives a hyperbolic dose-response curve in vitro
(Berry, 1964) although it is an alkylating agent and would be expected to give an
exponential curve in vivo. WVhatever the reasons for these discrepancies, they
reinforce the idea that evidence as to the modes ofaction ofthese agents obtained
in in vitro experiments canbe extrapolated to in vivo conditions onlywith consider-
able reservation.
SUMMARY
Many commonly used antitumour and immunosuppressive agents act by
impairing the reproductive integrity ofproliferating cells. The common assump-
tion that the relation between dose and cell survival for such agents is generally
exponential is incorrect. The dose-response curve for antimetabolites is shown to
be characteristically hyperbolic, i.e. the product of the surviving fraction of a
proliferating cell population and the dose of agent (or a power of the dose) is a
constant. The hyperbolic form ofthese curves is probably due to the competitive
nature ofantimetabolite action. Alkylating agents resemble radiation in showing
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exponential dose-response curves. Such curves may be expected when discrete
quanta of agent react independently and at random with critical cell targets.
I am indebted for support to the Leukaemia Research Fund, the Medical
Research Council, and the British Empire Cancer Campaign for Research.
Technical assistance was provided by Miss Rowena Baron.
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